Lilly's acquisition of Icos is a big bet on the future of private pay medicines. Lilly is paying $2.1 billion for sole rights to Cialis, in part because the company is happy to have a brand that operates outside of the influence of managed care gatekeepers in the US.
Count Eli Lilly & Co. as a believer in the future of private-pay in the pharma market: prescription-only medicines that fall outside the control of managed care gatekeepers in the US.
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Europe’s vaccines industry wants to make sure immunizations “are not forgotten” by policymakers who are overseeing the EU Health Technology Assessment Regulation. It has highlighted several nuances of vaccines that should be addressed over the coming years.
Wide-ranging executive order to lower drug prices also hints at changes in upcoming guidance on the Medicare price negotiation program but few other potentially impactful near-term actions.
Eisai is working on securing reimbursement across the EU for Leqembi now that the Alzheimer’s disease treatment has secured marketing approval from the European Commission.
The African Medicines Agency is to appoint a director general and become operational at the end of this month.
The preliminary White House 2026 budget plan cuts agency funding, but not so sharply that user fees are excluded from collection.
An investigation by the US Secretary of Commerce into pharmaceutical imports gives industry an opportunity to comment. AAM CEO John Murphy talked to Pink Sheet's sister publication Scrip about the latest developments.
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to include four new products, one of which is Tivdak, Pfizer/Genmab’s treatment for previously treated recurrent or metastatic cervical cancer.
